E-COMMERCE FUNCTIONALITY TEMPORARILY UNAVAILABLE. US CUSTOMERS PLEASE CALL 1-800-405-3362 TO PLACE AN ORDER.

REPROCELL’s Corporate History

August 2017Official opening of the "Centre for Predictive Drug Discovery" laboratories in Glasgow, Scotland
May 2017Alliance is formed with Fox Chase Medical Center (Philadelphia, U.S.A.) to accelerate biomarker and genetic discovery
November 2016Agreement is signed with Steminent Biopharmaceuticals (Taiwan) for Stemchymal cell therapy technology; REPROCELL Medical business unit is created
November 2016REPROCELL Europe founded with full-trading offices located at the Biopta site in Glasgow, Scotland (U.K.); Dr. David Bunton named CEO.
August 2016REPROCELL USA founded with full-trading offices located at the BioServe site in Beltsville, MD (U.S.A.); Dr. Rama Modali named CEO.
November 2015Acquired Biopta (Glasgow, Scotland, U.K.)
October 2014REPROCELL USA, the Company’s affiliate in the U.S.A., acquired the business of iPS cell business department of Stemgent (U.S.A.), and changed its name to Stemgent.
September 2014Acquired BioServe (Beltsville, MD, U.S.A.)
July 2014Acquired Reinnervate (County Durham, England, U.K.)
February 2014Consignment and entrustment agreement with Japan Blood Products Organization for the clinical laboratory measurement work.
February 2014Establishment of RC Partners, Inc., which is the Company’s affiliate to invest in a general partner of the venture capital fund called “Cell Innovation Partners, L.P.” that focuses on the creation of next-generation pharmaceutical and medical businesses.
November 2013Launch of custom-made disease model cells in collaboration with Takara Bio, Inc. (Cell products)
October 2013Shin-Yokohama District (REPROCELL, Inc) was chosen as the Life Innovation Comprehensive Special Zones for International Competitiveness Development.
June 2013Listed on the Osaka Securities Exchange JASDAQ Growth Market.
December 2012Establishment of the sales office of REPROCELL USA Inc. in Boston.
October 2012Professor Shinya Yamanaka of Kyoto University received the Nobel Prize in Physiology or Medicine.
August 2012Establishment of agreement for sales collaboration concerning human iPS cells model for Alzheimer’s disease with PerkinElmer Japan Co., Ltd.
June 2012Launch of human iPSC-derived neuron model cells for Alzheimer’s disease.
May 2012Human iPSC-derived hepatocytes (ReproHepato) launch
October 2011A new version of human iPSC-derived cardiomyocytes (ReproCardio2, frozen) launch
April 2011A new feeder-free culture medium ReproFF2 launched
April 2011REPROCELL USA, Ltd. established
October 2010Human iPSC-derived DA neuron (ReproNeuro DA) launch
January 2010The headquarters and laboratory have moved to Yokohama
April 2009Human iPSC-derived cardiomyocytes (ReproCardio) and the assay service using it (QTempo) launch
August 2008Cardiotoxicity testing (QTempo) using monkey ES cell-derived cardiomyocytes launch
July 2005National granted project with Kyoto University and pharmaceutical companies “Drug screening and toxicity technology using human ES cells” (2005 to 2010)
June 2005Laboratory installed in Tokyo
April 2005Launch of research reagent business: Primate ES cell medium
August 2004Start commercializing Nanog antibodies (human, mouse)
June 2003Joint research agreement with Kyoto University
May 2003Joint research agreement with Tokyo University
February 2003REPROCELL Inc. Established
Top